The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Detection of the misuse of rhGH has proved difficult for a number of reasons.

One of these is the effect of preceding exercise.

In this randomised, double blind placebo-controlled study, the researchers determined the effects of rhGH administration in male amateur athletes on two candidate markers of rhGH abuse, IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP), following a bout of weightlifting exercise.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, men only.

Sixteen men entered a four-week general weight training programme to homogenise their activity profile.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

They then undertook repeated bouts of standardised leg press weightlifting exercise (AHRET-acute heavy resistance exercise test).

What Was Measured

PubMed files the paper under topics including Athletes, Case-Control Studies, Collagen Type III, Exercise, Growth Hormone, Insulin-Like Growth Factor I and Resistance Training.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.